id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
3565435_1 | A 23-year-old woman with systemic lupus erythematosus had a severe hypersensitivity reaction to the drug ibuprofen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"hypersensitivity reaction\"]], \"start\": [[67]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ibuprofen\"]], \"start\": [[105]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"systemic lupus erythematosus\"]], \"start\": [[25]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"ibuprofen\"]], \"start\": [[105]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"A 23-year-old woman with systemic lupus erythematosus\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"23-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T3\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[60]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
2738729_1 | We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"case\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"WES\"]], \"start\": [[29]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"haloperidol\"]], \"start\": [[70]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"haloperidol\"]], \"start\": [[70]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"an infant born to a mother\"]], \"start\": [[36]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}}}"
}
]
}
] |
17189581_7 | Despite treatment with levofloxacin, acyclovir, and voriconazole, the patient developed high fevers. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[78]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"levofloxacin, acyclovir, and voriconazole\"]], \"start\": [[23]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"levofloxacin\"], [\"acyclovir\"], [\"voriconazole\"]], \"start\": [[23], [37], [52]], \"entity_id\": [\"T12\", \"T13\", \"T14\"]}}, \"Effect\": {\"text\": [[\"high fevers\"]], \"start\": [[88]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[70]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
6353252_2 | The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril-induced acute renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[132]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"The 5 patients had severe renovascular disease\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"5\"]], \"start\": [[4]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"renovascular disease\"]], \"start\": [[26]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"captopril\"]], \"start\": [[122]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[122]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[140]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"might\"]], \"start\": [[53]], \"entity_id\": [\"T3\"], \"value\": true}}"
}
]
}
] |
8691927_5 | METHODS: Growth retardation was observed in six severely asthmatic children after introduction of high-dose fluticasone propionate treatment (dry powder). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[76]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"six severely asthmatic children\"]], \"start\": [[44]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"six\"]], \"start\": [[44]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[67]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Growth retardation\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"introduction of high-dose fluticasone propionate treatment (dry powder)\"]], \"start\": [[82]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"severely asthmatic\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[98]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"fluticasone propionate\"]], \"start\": [[108]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"dry powder\"]], \"start\": [[142]], \"entity_id\": [\"T1\"]}}}"
}
]
}
] |
433855_1 | The toxic effects of methotrexate included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[18]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[21]], \"entity_id\": [\"T14\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[21]], \"entity_id\": [\"T17\"]}}, \"Effect\": {\"text\": [[\"toxic effects\", \"elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)\"]], \"start\": [[4, 43]], \"entity_id\": [\"T15\"]}, \"Severity\": {\"text\": [[\"mild\"]], \"start\": [[132]], \"entity_id\": [\"T16\"], \"value\": \"Low\"}}"
}
]
}
] |
20120657_1 | CONCLUSION: Zidovudine is well a known cause of anaemia and thus should be used with caution in the initiation of antiretroviral therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Zidovudine\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Zidovudine\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"anaemia\"]], \"start\": [[48]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
18676387_4 | A 60-yr-old woman, established on paroxetine for depression, underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"established\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 60-yr-old woman\", \"depression\"]], \"start\": [[0, 49]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"60-yr-old\"]], \"start\": [[2]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"paroxetine\", \"underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction\"]], \"start\": [[34, 61]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"paroxetine\"]], \"start\": [[34]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"depression\"], [\"myxofibrosarcoma\"]], \"start\": [[49], [96]], \"entity_id\": [\"T13\", \"T14\"]}}}"
}
]
}
] |
7397053_2 | Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Papilloedema and hepatic dysfunction\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"perhexiline maleate (Pexid)\"]], \"start\": [[59]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"perhexiline maleate\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
9103523_2 | The volatile anesthetic halothane undergoes substantial biotransformation generating metabolites that mediate hepatotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"mediate\"]], \"start\": [[102]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"volatile anesthetic halothane\"]], \"start\": [[4]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"halothane\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"volatile\"]], \"start\": [[4]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[110]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
10803790_4 | Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[77]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"elevation of serum transaminases\"]], \"start\": [[120]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"61-year-old male alcoholic who remained completely abstinent\"]], \"start\": [[10]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"61-year-old\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"cyanamide for 3 years\"]], \"start\": [[84]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"cyanamide\"]], \"start\": [[84]], \"entity_id\": [\"T11\"]}, \"Duration\": {\"text\": [[\"3 years\"]], \"start\": [[98]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"alcoholic\"]], \"start\": [[27]], \"entity_id\": [\"T1\"]}}}"
}
]
}
] |
1261772_3 | These observations indicate that submassive hepatic necrosis may result from treatment with propylthiouracil and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"result\"]], \"start\": [[65]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"submassive hepatic necrosis\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"propylthiouracil\"]], \"start\": [[92]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"propylthiouracil\"]], \"start\": [[92]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
6197014_2 | Two children with rheumatic fever developed anicteric hepatitis while on high-dose aspirin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"Two children with rheumatic fever\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[4]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"anicteric hepatitis\"]], \"start\": [[44]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"high-dose aspirin\"]], \"start\": [[73]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"rheumatic fever\"]], \"start\": [[18]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"aspirin\"]], \"start\": [[83]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[73]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
12095907_1 | The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"an 88-year-old man\"]], \"start\": [[83]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"88-year-old\"]], \"start\": [[86]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[98]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[21]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[21]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"hyperammonemia and mental status changes\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
9831311_5 | The mechanism of the decrease in plasma potassium induced by phosphate treatment was investigated in a 24-year-old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[50]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"decrease in plasma potassium\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"phosphate treatment\"]], \"start\": [[61]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"phosphate\"]], \"start\": [[61]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"hypophosphatemic osteomalacia\"]], \"start\": [[141]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"a 24-year-old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations\"]], \"start\": [[101]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"24-year-old\"]], \"start\": [[103]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"hypertensive\"]], \"start\": [[115]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
1722991_6 | In the two cases, a combination of iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole was shown to inhibit ex vivo the heparin-induced platelet aggregation. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"inhibit ex vivo\"]], \"start\": [[137]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[7]], \"entity_id\": [\"T11\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[7]], \"entity_id\": [\"T14\"]}}, \"Treatment\": {\"text\": [[\"iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole\"]], \"start\": [[35]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"heparin-induced platelet aggregation\"]], \"start\": [[157]], \"entity_id\": [\"T13\"]}, \"Dosage\": {\"text\": [[\"1 to 2 ng/kg/mn\"]], \"start\": [[77]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"iloprost\"], [\"aspirin\"], [\"dipyridamole\"]], \"start\": [[35], [99], [111]], \"entity_id\": [\"T15\", \"T17\", \"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[94]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"iloprost\"], [\"aspirin\"], [\"dipyridamole\"]], \"start\": [[35], [99], [111]], \"entity_id\": [\"T15\", \"T17\", \"T18\"]}}]}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[165]], \"entity_id\": [\"T1\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[157]], \"entity_id\": [\"T2\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[157]], \"entity_id\": [\"T3\"]}}, \"Effect\": {\"text\": [[\"platelet aggregation\"]], \"start\": [[173]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
3067748_1 | Adrenaline dacryolith: detection by ultrasound examination of the nasolacrimal duct. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Adrenaline dacryolith\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"dacryolith\"]], \"start\": [[11]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Adrenaline\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Adrenaline\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"nasolacrimal duct\"]], \"start\": [[66]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
16012330_7 | Ten days after itraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[44]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"itraconazole\"]], \"start\": [[15]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[15]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities\"]], \"start\": [[54]], \"entity_id\": [\"T10\"]}, \"Severity\": {\"text\": [[\"severe\"], [\"mild\"], [\"mild\"]], \"start\": [[144], [190], [91]], \"entity_id\": [\"T12\", \"T13\", \"T14\"], \"value\": \"Medium\"}}"
}
]
}
] |
11328247_3 | OBJECTIVE: The aim of this paper is to describe a case of increased libido during fluvoxamine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[75]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"fluvoxamine therapy.\"]], \"start\": [[82]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"fluvoxamine\"]], \"start\": [[82]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"increased libido\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11131346_3 | An 8-year-old child with familial Mediterranean fever exhibited signs of colchicine intoxication while receiving prophylactic doses of the drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exhibited\"]], \"start\": [[54]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"An 8-year-old child\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"8-year-old\"], [\"child\"]], \"start\": [[3], [14]], \"entity_id\": [\"T11\", \"T12\"]}}, \"Effect\": {\"text\": [[\"colchicine intoxication\"]], \"start\": [[73]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"prophylactic doses of the drug\"]], \"start\": [[113]], \"entity_id\": [\"T9\"], \"Dosage\": {\"text\": [[\"prophylactic doses\"]], \"start\": [[113]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"familial Mediterranean fever\"]], \"start\": [[25]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"colchicine\"]], \"start\": [[73]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11675845_9 | Furthermore, the warfarin dose was again increased after discontinuation of ropinirole due to common gastrointestinal adverse effects. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[87]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"the warfarin dose was again increased after discontinuation of ropinirole\"]], \"start\": [[13]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"gastrointestinal adverse effects\"]], \"start\": [[101]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[17]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
25671244_1 | Serotonin syndrome following metaxalone overdose and therapeutic use of a selective serotonin reuptake inhibitor. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"metaxalone overdose\"]], \"start\": [[29]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"metaxalone\"], [\"selective serotonin reuptake inhibitor\"]], \"start\": [[29], [74]], \"entity_id\": [\"T9\", \"T11\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[40]], \"entity_id\": [\"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[49]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"metaxalone\"], [\"selective serotonin reuptake inhibitor\"]], \"start\": [[29], [74]], \"entity_id\": [\"T9\", \"T11\"]}}]}}"
}
]
}
] |
11700998_2 | The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[211]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"an elderly woman\"]], \"start\": [[96]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[99]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[107]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"nonconvulsive generalized status epilepticus\"]], \"start\": [[166]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"acute withdrawal of lorazepam\"]], \"start\": [[221]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"lorazepam\"]], \"start\": [[241]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
9634122_4 | We describe a patient with androgen-independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[124]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient with androgen-independent prostate cancer\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"PSA continued to decrease for a period of 15 months\"]], \"start\": [[72]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"flutamide withdrawal\"]], \"start\": [[130]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"flutamide\"]], \"start\": [[130]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"androgen-independent prostate cancer\"]], \"start\": [[27]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
19203515_1 | Acute renal failure following intravenous immunoglobulin therapy in a HIV-infected patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a HIV-infected patient\"]], \"start\": [[68]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"HIV\"]], \"start\": [[70]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"intravenous immunoglobulin therapy\"]], \"start\": [[30]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"immunoglobulin\"]], \"start\": [[42]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[30]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"Acute renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17189581_11 | After a total of four doses of linezolid, the patient reported further discomfort. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"a total of four doses of linezolid\"]], \"start\": [[6]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[31]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"four doses\"]], \"start\": [[17]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"further discomfort\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
19018868_2 | Although moderate myelosuppression is not uncommonly seen in patients treated with lenalidomide, aplastic anemia has not previously been reported to be associated with this agent. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[152]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lenalidomide\"]], \"start\": [[83]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"lenalidomide\"]], \"start\": [[83]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"aplastic anemia\"]], \"start\": [[97]], \"entity_id\": [\"T4\"]}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[117]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
18176653_11 | This paper contributed to the identification of possible reactions in the oral cavity due to antiretroviral medication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[86]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"antiretroviral medication\"]], \"start\": [[93]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"antiretroviral medication\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"reactions in the oral cavity\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[48]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
2076372_1 | Persistent light reactivity from systemic quinine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"from\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Persistent light reactivity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"systemic quinine\"]], \"start\": [[33]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"quinine\"]], \"start\": [[42]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
15482394_2 | Based on the clinical status of the patient, it was suspected that several conditions contributed to the abnormal hypersensitivity to warfarin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[131]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"abnormal hypersensitivity\"]], \"start\": [[105]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[134]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[134]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[52]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
17852449_3 | Treatment of APL in pregnancy is controversial as the use of ATRA has been questioned due to the teratogenic effect of retinoids. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[86]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"retinoids\"]], \"start\": [[119]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"retinoids\"]], \"start\": [[119]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"teratogenic effect\"]], \"start\": [[97]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"questioned\"]], \"start\": [[75]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
2302898_1 | Diazepam use by pregnant women can be associated with a later presentation of withdrawal symptoms in the neonate than that induced by the use of other drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"later presentation of withdrawal symptoms in the neonate\"]], \"start\": [[56]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"neonate\"]], \"start\": [[105]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"neonate\"]], \"start\": [[105]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"Diazepam\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Diazepam\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
17381671_3 | A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[108]], \"entity_id\": [\"T20\"]}, \"Subject\": {\"text\": [[\"A 65-year-old patient\"]], \"start\": [[0]], \"entity_id\": [\"T17\"], \"Age\": {\"text\": [[\"65-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T21\"]}}, \"Treatment\": {\"text\": [[\"chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram\", \"following initiation of fentanyl\"]], \"start\": [[22, 233]], \"entity_id\": [\"T18\"], \"Drug\": {\"text\": [[\"citalopram\"], [\"fentanyl\"]], \"start\": [[97], [257]], \"entity_id\": [\"T22\", \"T25\"]}, \"Time_elapsed\": {\"text\": [[\"chronically\"]], \"start\": [[22]], \"entity_id\": [\"T26\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[233]], \"entity_id\": [\"T24\"]}, \"Drug\": {\"text\": [[\"citalopram\"], [\"fentanyl\"]], \"start\": [[97], [257]], \"entity_id\": [\"T22\", \"T25\"]}}]}, \"Effect\": {\"text\": [[\"confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome\"]], \"start\": [[118]], \"entity_id\": [\"T19\"]}}"
}
]
}
] |
21712512_11 | This case highlights rapid onset of adrenal insufficiency in a patient with CF-related liver disease treated briefly with a moderate CYP3A4 inhibitor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"onset\"]], \"start\": [[27]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"a patient with CF-related liver disease\"]], \"start\": [[61]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"briefly with a moderate CYP3A4 inhibitor\"]], \"start\": [[109]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"CYP3A4 inhibitor\"]], \"start\": [[133]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"CF-related liver disease\"]], \"start\": [[76]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"rapid onset of adrenal insufficiency\"]], \"start\": [[21]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
847572_2 | The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"remarked\"]], \"start\": [[159]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"alcoholic patients\"]], \"start\": [[95]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"hepatotoxic effects\"]], \"start\": [[121]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"paracetamol\"]], \"start\": [[144]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"paracetamol\"]], \"start\": [[144]], \"entity_id\": [\"T5\"]}}}"
}
]
}
] |
12951892_2 | The newborn manifested a four day course of lethargy with unexplained high lithium levels in the adult toxic range. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"manifested\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"four day course of lethargy with unexplained high lithium levels\"]], \"start\": [[25]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lithium\"]], \"start\": [[75]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[75]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"newborn\"]], \"start\": [[4]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"newborn\"]], \"start\": [[4]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8891729_3 | The occurrence of severe AIHA in CLL patients treated with fludarabine has been reported by several authors. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[46]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"fludarabine\"]], \"start\": [[59]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"CLL\"]], \"start\": [[33]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"fludarabine\"]], \"start\": [[59]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"severe AIHA\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"CLL patients\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[18]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
19034138_4 | Corneal endothelial dysfunction associated with amantadine toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Corneal endothelial dysfunction\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"amantadine\"]], \"start\": [[48]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"amantadine\"]], \"start\": [[48]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
1378497_4 | We describe the development of cutaneous scleroderma in 3 patients coincident with the use of bleomycin in low cumulative doses of less than 100 U. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[16]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"cutaneous scleroderma\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"3 patients\"]], \"start\": [[56]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"the use of bleomycin in low cumulative doses of less than 100 U\"]], \"start\": [[83]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bleomycin\"]], \"start\": [[94]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"less than 100 U\"]], \"start\": [[131]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
10367184_3 | This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"interact\"]], \"start\": [[111]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"humans.\"]], \"start\": [[183]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"severe clinical myotonia\"]], \"start\": [[155]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"pravastatin\"]], \"start\": [[40]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"pravastatin\"]], \"start\": [[40]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[107]], \"entity_id\": [\"T8\"], \"value\": true}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[155]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}"
}
]
}
] |
7226916_2 | Disopyramide-induced heart block. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Disopyramide\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Disopyramide\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"heart block\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
578255_2 | Telescoped digits of the hands and feet developed in a 69-year-old male with severe chronic tophaceous gout during allopurinol treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[40]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a 69-year-old male with severe chronic tophaceous gout\"]], \"start\": [[53]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"69-year-old\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Telescoped digits of the hands and feet\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"allopurinol treatment\"]], \"start\": [[115]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"severe chronic tophaceous gout\"]], \"start\": [[77]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"allopurinol\"]], \"start\": [[115]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
8742573_2 | CONCLUSIONS: Jet-injection devices might constitute a helpful method to treat those patients affected by severe human insulin-induced lipoatrophy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treat\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Jet-injection devices\"]], \"start\": [[13]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"insulin-induced lipoatrophy\"]], \"start\": [[118]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"Jet-injection\"]], \"start\": [[13]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[84]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"might\"]], \"start\": [[35]], \"entity_id\": [\"T7\"], \"value\": true}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[126]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"lipoatrophy\"]], \"start\": [[134]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"insulin\"]], \"start\": [[118]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"insulin\"]], \"start\": [[118]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[105]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
20412003_6 | We describe a relatively healthy, 9-year-old boy who developed a CA-MRSA skin and soft tissue infection and was treated with TMP-SMX. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[112]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"TMP-SMX\"]], \"start\": [[125]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"CA-MRSA skin and soft tissue infection\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"TMP-SMX\"]], \"start\": [[125]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"a relatively healthy, 9-year-old boy\"]], \"start\": [[12]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"9-year-old\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[45]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
10897389_2 | Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"cyclosporine\"]], \"start\": [[58]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"severe ulcerative colitis\"]], \"start\": [[82]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"cyclosporine\"]], \"start\": [[58]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Recurrent septicemia with lethal outcome\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Severity\": {\"text\": [[\"lethal\"]], \"start\": [[26]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
14740795_2 | Amifostine-induced fever: case report and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Amifostine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Amifostine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"fever\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16767537_3 | We report a patient who developed spontaneous splenic infarction after the use of sumatriptan for the treatment of migraine headache. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"spontaneous splenic infarction\"]], \"start\": [[34]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"sumatriptan\"]], \"start\": [[82]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"migraine headache\"]], \"start\": [[115]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"sumatriptan\"]], \"start\": [[82]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
12590235_2 | Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Hepatotoxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"6-thioguanine\"]], \"start\": [[31]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"6-thioguanine\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[57]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15694139_4 | Neuropathy is a significant side effect of thalidomide therapy, which may limit its clinical use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side effect\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Neuropathy\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"thalidomide\"]], \"start\": [[43]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"thalidomide\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"significant\"]], \"start\": [[16]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
6414095_5 | A possible mechanism for focal neurological deficit in brain-damaged patients on phenytoin therapy is discussed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"mechanism\"]], \"start\": [[11]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"phenytoin therapy\"]], \"start\": [[81]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[81]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"brain-damaged\"]], \"start\": [[55]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"focal neurological deficit\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"brain-damaged patients\"]], \"start\": [[55]], \"entity_id\": [\"T1\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[2]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
11757641_1 | Pulmonary toxicity with mefloquine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Pulmonary toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"mefloquine\"]], \"start\": [[24]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"mefloquine\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2327115_1 | Ciprofloxacin is one drug that has been reported to cause interstitial nephritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[52]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"interstitial nephritis\"]], \"start\": [[58]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16945058_1 | Acute renal failure during lisinopril and losartan therapy for proteinuria. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Acute renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"lisinopril and losartan\"]], \"start\": [[27]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"proteinuria\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"lisinopril\"], [\"losartan\"]], \"start\": [[27], [42]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[38]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"lisinopril\"], [\"losartan\"]], \"start\": [[27], [42]], \"entity_id\": [\"T8\", \"T9\"]}}]}}"
}
]
}
] |
9497597_2 | We present the first case of a patient with priapism after oral intake of the phenothiazine prothipendylhydrochloride. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[29]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"priapism\"]], \"start\": [[44]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"oral intake of the phenothiazine prothipendylhydrochloride\"]], \"start\": [[59]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"prothipendylhydrochloride\"]], \"start\": [[92]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[59]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
12811715_3 | However, because diphenhydramine also exhibits type IA sodium channel blockade, cardiac toxicity is also possible. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"because\"]], \"start\": [[9]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"diphenhydramine\"]], \"start\": [[17]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"diphenhydramine\"]], \"start\": [[17]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"also exhibits type IA sodium channel blockade, cardiac toxicity\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Speculated\": {\"text\": [[\"also possible\"]], \"start\": [[100]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
11399735_3 | Ticlopidine-induced interstitial pulmonary disease: a case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Ticlopidine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Ticlopidine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"interstitial pulmonary disease\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19226083_16 | Linezolid is a popular choice of antibiotic, especially for the treatment of orthopedic-related MRSA infections. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"orthopedic-related MRSA infections\"]], \"start\": [[77]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Linezolid\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
14711147_4 | We present a case of photo-onycholysis in a patient treated with doxycycline for acne vulgaris. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"doxycycline\"]], \"start\": [[65]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"doxycycline\"]], \"start\": [[65]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"acne vulgaris\"]], \"start\": [[81]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"photo-onycholysis\"]], \"start\": [[21]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
15097937_2 | Anticonvulsant hypersensitivity syndrome associated with Bellamine S, a therapy for menopausal symptoms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Anticonvulsant hypersensitivity syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Bellamine S, a therapy for menopausal symptoms\"]], \"start\": [[57]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"menopausal symptoms.\"]], \"start\": [[84]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Bellamine S\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9161656_3 | CASE SUMMARY: A 66-year-old white woman with a 10-year history of hypertension and bronchial asthma was switched from immediate-release verapamil hydrocloride 40 mg tid to sustained-release verapamil 240 mg/d po for better hypertension control. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"control\"]], \"start\": [[236]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"A 66-year-old white woman with a 10-year history of hypertension and bronchial asthma\"]], \"start\": [[14]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"66-year-old\"]], \"start\": [[16]], \"entity_id\": [\"T12\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[28]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[34]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"bronchial asthma\"]], \"start\": [[83]], \"entity_id\": [\"T16\"]}}, \"Treatment\": {\"text\": [[\"switched from immediate-release verapamil hydrocloride 40 mg tid to sustained-release verapamil 240 mg/d po\"]], \"start\": [[104]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"hypertension\"], [\"hypertension\"]], \"start\": [[66], [223]], \"entity_id\": [\"T15\", \"T1\"]}, \"Drug\": {\"text\": [[\"immediate-release verapamil hydrocloride\"], [\"sustained-release verapamil\"]], \"start\": [[118], [172]], \"entity_id\": [\"T11\", \"T17\"]}, \"Dosage\": {\"text\": [[\"240 mg/d\"], [\"40 mg tid\"]], \"start\": [[200], [159]], \"entity_id\": [\"T18\", \"T19\"]}, \"Route\": {\"text\": [[\"po\"]], \"start\": [[209]], \"entity_id\": [\"T22\"]}}}"
}
]
}
] |
18294121_3 | Due to the severity of the rash, temozolomide was permanently discontinued. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Due\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"temozolomide\"]], \"start\": [[33]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"temozolomide\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"rash\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"severity\"]], \"start\": [[11]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
7835785_1 | Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[102]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Ovarian endometrioid carcinoma and endometriosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a postmenopausal breast cancer patient\"]], \"start\": [[63]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"postmenopausal\"]], \"start\": [[65]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"tamoxifen therapy\"]], \"start\": [[109]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[109]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[80]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
18585545_2 | CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and insomnia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[197]], \"entity_id\": [\"T22\"]}, \"Effect\": {\"text\": [[\"central nervous system-related adverse effects, including headache, dizziness and insomnia\"]], \"start\": [[203]], \"entity_id\": [\"T23\"]}, \"Treatment\": {\"text\": [[\"The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors\"]], \"start\": [[12]], \"entity_id\": [\"T24\"], \"Drug\": {\"text\": [[\"levofloxacin\"], [\"sparfloxacin\"], [\"grepafloxacin\"], [\"trovafloxacin\"], [\"gatifloxacin\"], [\"moxifloxacin\"]], \"start\": [[43], [57], [71], [86], [101], [118]], \"entity_id\": [\"T25\", \"T26\", \"T27\", \"T28\", \"T29\", \"T30\"]}}}"
}
]
}
] |
18609153_1 | Terlipressin-induced ventricular arrhythmia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Terlipressin\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Terlipressin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"ventricular arrhythmia\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17228132_4 | CASE REPORT: We report a case of acute severe hepatitis resulting from erlotinib monotherapy in a patient with locally advanced pancreatic cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"acute severe hepatitis\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"erlotinib monotherapy\"]], \"start\": [[71]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[71]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"locally advanced pancreatic cancer\"]], \"start\": [[111]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"a patient with locally advanced pancreatic cancer\"]], \"start\": [[96]], \"entity_id\": [\"T9\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[39]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
16914372_1 | We highlight two instances of systemic allergic reaction, and discuss the potential side effects of local aprotinin injections in the orthopaedic setting as well as the evidence base for its use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[97]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two instances\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"systemic allergic reaction\", \"potential side effects\"]], \"start\": [[30, 74]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"aprotinin\"]], \"start\": [[106]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"aprotinin\"]], \"start\": [[106]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"injections\"]], \"start\": [[116]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[74]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
7962394_1 | Acute pancreatitis associated with danazol treatment for endometriosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Acute pancreatitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"danazol treatment\"]], \"start\": [[35]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"endometriosis\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}}, \"Severity\": {\"text\": [[\"Acute\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
14526130_2 | CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and betamethasone, manifested acute pancreatitis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"manifested\"]], \"start\": [[126]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 58 year old patient\"]], \"start\": [[35]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"58 year old\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"after 2 days of treatment with roxithromycin\", \"betamethasone\"]], \"start\": [[62, 111]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"roxithromycin\"], [\"betamethasone\"]], \"start\": [[93], [111]], \"entity_id\": [\"T9\", \"T10\"]}, \"Time_elapsed\": {\"text\": [[\"2 days\"]], \"start\": [[68]], \"entity_id\": [\"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[107]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"roxithromycin\"], [\"betamethasone\"]], \"start\": [[93], [111]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[137]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
576675_3 | It should be recognized that ibuprofen may be associated with salt and water retention in the same fashion as previously described with phenylbutazone and indomethacin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"salt and water retention\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"ibuprofen\"]], \"start\": [[29]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ibuprofen\"], [\"phenylbutazone\"], [\"indomethacin\"]], \"start\": [[29], [136], [155]], \"entity_id\": [\"T8\", \"T9\", \"T10\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[39]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
18459568_1 | Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"detected\"]], \"start\": [[78]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"tamoxifen\"]], \"start\": [[108]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[122]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[108]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"Gastric tumor, endometrial carcinoma and cervical adenocarcinoma in situ\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
18665833_2 | This therapy was also complicated by Warfarin-induced skin necrosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[46]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Warfarin\"]], \"start\": [[37]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Warfarin\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"skin necrosis\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10048291_1 | Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by rifampicin, could have led to increased calcium-release into the circulation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"led\"]], \"start\": [[136]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"dihydrotachysterol\"]], \"start\": [[91]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"dihydrotachysterol\"]], \"start\": [[91]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"increased calcium-release\"]], \"start\": [[143]], \"entity_id\": [\"T3\"]}, \"Speculated\": {\"text\": [[\"enhanced\"]], \"start\": [[68]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
8949576_2 | Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[105]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[94]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[94]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"thyroiditis\"]], \"start\": [[113]], \"entity_id\": [\"T5\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"ameliorate\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"plasmapheresis, corticosteroids and thionamides\"]], \"start\": [[11]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"amiodarone-induced thyroiditis\"]], \"start\": [[94]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"thionamides\"]], \"start\": [[27], [47]], \"entity_id\": [\"T11\", \"T12\"]}}, \"Negated\": {\"text\": [[\"Failure\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
15162903_1 | Although neurotoxicity is a frequent complication of methotrexate therapy, fatal acute neurotoxicity is extremely uncommon, especially in adults. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[37]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"neurotoxicity\"]], \"start\": [[9]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"methotrexate therapy\"]], \"start\": [[53]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
566977_3 | Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated metabolic acidosis due to absorbed formic acid. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[119]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"metabolic acidosis\"]], \"start\": [[100]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"absorbed formic acid\"]], \"start\": [[126]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"formic acid\"]], \"start\": [[135]], \"entity_id\": [\"T7\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"combating\"]], \"start\": [[75]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"Intravenous sodium bicarbonate\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"metabolic acidosis due to absorbed formic acid\"]], \"start\": [[100]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"Intravenous\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"sodium bicarbonate\"]], \"start\": [[12]], \"entity_id\": [\"T13\"]}}, \"Speculated\": {\"text\": [[\"appears to\"]], \"start\": [[31]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
578255_1 | Allopurinol-associated hand and foot deformities in chronic tophaceous gout. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Allopurinol\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Allopurinol\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"chronic tophaceous gout\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hand and foot deformities\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
11022272_3 | The intramuscular challenge test with 25 UI of Miacalcic was positive with an immediate anaphylactic reaction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reaction\"]], \"start\": [[101]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"25 UI of Miacalcic\", \"immediate\"]], \"start\": [[38, 78]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Miacalcic\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"25 UI\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"immediate\"]], \"start\": [[78]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"anaphylactic reaction\"]], \"start\": [[88]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
19226083_4 | There are several documented case reports of serotonin toxicity when used with selective serotonin reuptake inhibitors. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reports\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"selective serotonin reuptake inhibitors\"]], \"start\": [[79]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"selective serotonin reuptake inhibitors\"], [\"serotonin\"]], \"start\": [[79], [45]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[74]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"selective serotonin reuptake inhibitors\"], [\"serotonin\"]], \"start\": [[79], [45]], \"entity_id\": [\"T7\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"serotonin toxicity\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"several documented case\"]], \"start\": [[10]], \"entity_id\": [\"T10\"], \"Population\": {\"text\": [[\"several\"]], \"start\": [[10]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
4082283_6 | A literature review revealed 83 other reported cases of rifampicin-induced renal insufficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[67]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"rifampicin\"]], \"start\": [[56]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[56]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"renal insufficiency\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"83 other reported cases\"]], \"start\": [[29]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"83\"]], \"start\": [[29]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8485005_1 | Complete regression of iatrogenic Kaposi's sarcoma due to corticosteroid treatment in a patient with tubercular pericarditis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"regression\"]], \"start\": [[9]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"corticosteroid\"]], \"start\": [[58]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"Kaposi's sarcoma\"]], \"start\": [[34]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"corticosteroid\"]], \"start\": [[58]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"a patient with tubercular pericarditis\"]], \"start\": [[86]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"tubercular pericarditis\"]], \"start\": [[101]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16757971_1 | DIAGNOSIS: Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"temozolomide\", \"exacerbated by corticosteroids\"]], \"start\": [[18, 58]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"temozolomide\"], [\"corticosteroids\"]], \"start\": [[18], [73]], \"entity_id\": [\"T18\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"exacerbated\"]], \"start\": [[58]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"temozolomide\"]], \"start\": [[73], [18]], \"entity_id\": [\"T19\", \"T18\"]}}]}, \"Effect\": {\"text\": [[\"immunosuppression\"], [\"T-cell lymphocytopenia\"], [\"Pneumocystis jiroveci pneumonia\"], [\"brain abscess with Listeria monocytogenes\"], [\"cutaneous Kaposi's sarcoma\"]], \"start\": [[39], [104], [174], [207], [254]], \"entity_id\": [\"T13\", \"T14\", \"T15\", \"T16\", \"T17\"]}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[11]], \"entity_id\": [\"T21\"], \"value\": \"High\"}}"
}
]
}
] |
17163271_3 | The use of cyclosporin has been associated with the development of cholelithiasis in transplant recipients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[52]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"cholelithiasis\"]], \"start\": [[67]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"transplant recipients\"]], \"start\": [[85]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"transplant\"]], \"start\": [[85]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"cyclosporin\"]], \"start\": [[11]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cyclosporin\"]], \"start\": [[11]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
3200786_1 | Rifampicin-induced adrenal insufficiency in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Rifampicin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Rifampicin\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"adrenal insufficiency\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
19235747_2 | Bisphosphonate-related osteonecrosis of the skull base. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Bisphosphonate\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Bisphosphonate\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"osteonecrosis of the skull base\"]], \"start\": [[23]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
14641354_1 | Angioedema and dysphagia caused by contact allergy to inhaled budesonide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"inhaled\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"contact allergy\", \"Angioedema and dysphagia\"]], \"start\": [[35, 0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"budesonide\"]], \"start\": [[62]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"budesonide\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
12656748_2 | Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[68]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Emergence of Philadelphia positive chronic myeloid leukaemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[83]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[83]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"Philadelphia negative essential thrombocythaemia\"]], \"start\": [[99]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
15592331_1 | Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"increases\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Ciprofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Ciprofloxacin\"], [\"tizanidine\"]], \"start\": [[0], [73]], \"entity_id\": [\"T9\", \"T10\"]}}, \"Effect\": {\"text\": [[\"concentrations and hypotensive effect of tizanidine\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10426918_1 | 2-CdA induces lymphocytopenia, which may explain the improvement in this patient's psoriasis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"induces\"]], \"start\": [[6]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"patient's psoriasis\"]], \"start\": [[73]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"2-CdA\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"2-CdA\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"psoriasis\"]], \"start\": [[83]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"lymphocytopenia\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[37]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
7831179_2 | There is a dose-effect relationship between doxorubicin and the incidence of symptomatic cardiac failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"relationship\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"doxorubicin\"]], \"start\": [[44]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"doxorubicin\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"symptomatic cardiac failure\"]], \"start\": [[77]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
19145124_2 | These are the first reported patients to show mfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that ethambutol damages the retina. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"evidence\"]], \"start\": [[140]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[154]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[154]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"damages the retina\"]], \"start\": [[165]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19949685_3 | Two days after administration of Kalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[9]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Two days after administration of Kalimate enema\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"enema\"]], \"start\": [[42]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"Kalimate\"]], \"start\": [[33]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"Two days\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[49]], \"entity_id\": [\"T7\"], \"Gender\": {\"text\": [[\"he\"]], \"start\": [[49]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"profuse hematochezia\", \"diffuse colonic mucosal necrosis in the rectum\"]], \"start\": [[56, 105]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
18191947_1 | Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[65]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[52]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"sub-acute neurotoxicity\"]], \"start\": [[73]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
14760958_1 | Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"on\"]], \"start\": [[78]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"interferon beta-1a\"]], \"start\": [[81]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"interferon beta-1a\"]], \"start\": [[81]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"multiple sclerosis\"]], \"start\": [[33]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Scleromyxedema\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient with multiple sclerosis and monoclonal gammopathy\"]], \"start\": [[18]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"monoclonal gammopathy\"]], \"start\": [[56]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9494448_8 | The literature search revealed 22 cases of hypersensitivity reaction to cyclosporine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[69]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"22 cases\"]], \"start\": [[31]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"22\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity reaction\"]], \"start\": [[43]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cyclosporine\"]], \"start\": [[72]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cyclosporine\"]], \"start\": [[72]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9184269_6 | The presence of a lymphocyte alveolitis with a predominance of CD4+ T cells in 3 RA patients and CD8+ T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in MTX-induced pneumonitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[253]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[249]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"RA\"]], \"start\": [[81]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[249]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"a lymphocyte alveolitis with a predominance of CD4+ T cells\", \"pneumonitis\", \"CD8+ T cells with a concomitant increase in neutrophils\"]], \"start\": [[16, 261, 97]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"3 RA patients\"]], \"start\": [[79]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[79]], \"entity_id\": [\"T5\"]}}}"
}
]
}
] |
11972105_1 | The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[52]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"delayed elimination\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[55]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"patients receiving ciprofloxacin\"]], \"start\": [[71]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[110]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
2329972_2 | Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Severe acute encephalopathy\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"intrathecal doxorubicin administration\"]], \"start\": [[50]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"doxorubicin\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"value\": \"High\"}}"
}
]
}
] |
11886466_2 | Porcine factor VIII (pFVIII), which is used to control bleeding in patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII, is not known to increase the risk of arterial or venous thrombosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"increase\"]], \"start\": [[192]], \"entity_id\": [\"T15\"]}, \"Effect\": {\"text\": [[\"risk of arterial or venous thrombosis.\"]], \"start\": [[205]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"Porcine factor VIII (pFVIII)\"]], \"start\": [[0]], \"entity_id\": [\"T17\"], \"Disorder\": {\"text\": [[\"high-titre neutralizing antibodies to human FVIII\"], [\"bleeding\"], [\"congenital or acquired haemophilia\"]], \"start\": [[125], [55], [81]], \"entity_id\": [\"T21\", \"T28\", \"T19\"]}, \"Drug\": {\"text\": [[\"Porcine factor VIII\"]], \"start\": [[0]], \"entity_id\": [\"T24\"]}}, \"Subject\": {\"text\": [[\"patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII\"]], \"start\": [[67]], \"entity_id\": [\"T18\"]}, \"Speculated\": {\"text\": [[\"risk\"]], \"start\": [[205]], \"entity_id\": [\"T23\"], \"value\": true}, \"Negated\": {\"text\": [[\"not\"]], \"start\": [[179]], \"entity_id\": [\"T22\"], \"value\": true}}"
}
]
}
] |
4031907_1 | In all the patients, pellagra symptoms appeared during isoniazid therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"appeared\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"all the patients\"]], \"start\": [[3]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"pellagra symptoms\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"isoniazid therapy\"]], \"start\": [[55]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"isoniazid\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
19904536_1 | Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[18]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"gemcitabine\"]], \"start\": [[6]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[6]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"metastatic gallbladder adenocarcinoma\"]], \"start\": [[48]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"pulmonary toxicity\"]], \"start\": [[26]], \"entity_id\": [\"T10\"]}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.